{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:18:28Z","timestamp":1791397108535,"version":"4.3.3"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Bayer HealthCare Pharmaceuticals Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41391-025-01054-8","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:11:28Z","timestamp":1765296688000},"page":"558-566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal","family":"Shore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6563-4587","authenticated-orcid":false,"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noman","family":"Paracha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Thom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Aceituno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Orishaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Stefani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quoc-Dien","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-4026","authenticated-orcid":false,"given":"Christopher J. D.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R.","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Boegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"1054_CR1","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMra1701695","volume":"378","author":"O Sartor","year":"2018","unstructured":"Sartor O, de Bono JS. Metastatic Prostate Cancer. N Engl J Med. 2018;378:645\u201357.","journal-title":"N Engl J Med"},{"key":"1054_CR2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017;377:352\u201360.","journal-title":"N Engl J Med"},{"key":"1054_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019;381:121\u201331.","journal-title":"N Engl J Med"},{"key":"1054_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019;381:13\u201324.","journal-title":"N Engl J Med"},{"key":"1054_CR5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med. 2017;377:338\u201351.","journal-title":"N Engl J Med"},{"key":"1054_CR6","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","volume":"29","author":"MR Sydes","year":"2018","unstructured":"Sydes MR, Spears MR, Mason MD, Clarke NW, Dearnaley DP, de Bono JS, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018;29:1235\u201348.","journal-title":"Ann Oncol"},{"key":"1054_CR7","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.annonc.2020.01.002","volume":"31","author":"NW Clarke","year":"2020","unstructured":"Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, et al. Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003. Ann Oncol. 2020;31:442.","journal-title":"Ann Oncol"},{"key":"1054_CR8","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Flechon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2022;399:1695\u2013707.","journal-title":"Lancet"},{"key":"1054_CR9","doi-asserted-by":"crossref","unstructured":"Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol. 2024;42:4271\u201381.","DOI":"10.1200\/JCO-24-01798"},{"key":"1054_CR10","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380:1235\u201346.","journal-title":"N Engl J Med"},{"key":"1054_CR11","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386:1132\u201342.","journal-title":"N Engl J Med"},{"key":"1054_CR12","unstructured":"Whippany NJBHPI. NUBEQA\u00ae (darolutamide) [Prescribing Information]. 2025."},{"key":"1054_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-022-02137-6","volume":"11","author":"DJ Fisher","year":"2022","unstructured":"Fisher DJ, Burdett S, Vale C, White IR, Tierney JF. Duplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change. Syst Rev. 2022;11:274.","journal-title":"Syst Rev"},{"key":"1054_CR14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.eururo.2022.08.002","volume":"82","author":"T Yanagisawa","year":"2022","unstructured":"Yanagisawa T, Rajwa P, Thibault C, Gandaglia G, Mori K, Kawada T, et al. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2022;82:584\u201398.","journal-title":"Eur Urol"},{"key":"1054_CR15","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/annonc\/mdy071","volume":"29","author":"CL Vale","year":"2018","unstructured":"Vale CL, Fisher DJ, White IR, Carpenter JR, Burdett S, Clarke NW, et al. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann Oncol. 2018;29:1249\u201357.","journal-title":"Ann Oncol"},{"key":"1054_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.euo.2022.04.007","volume":"5","author":"D Menges","year":"2022","unstructured":"Menges D, Yebyo HG, Sivec-Muniz S, Haile SR, Barbier MC, Tomonaga Y, et al. Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment. Eur Urol Oncol. 2022;5:605\u201316.","journal-title":"Eur Urol Oncol"},{"key":"1054_CR17","doi-asserted-by":"crossref","unstructured":"Hoeh B, Wenzel M, Tian Z, Karakiewicz PI, Saad F, Steuber T, et al. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE Data. Eur Urol Focus. 2024;11:386\u201390.","DOI":"10.1016\/j.euf.2024.11.004"},{"key":"1054_CR18","doi-asserted-by":"crossref","unstructured":"Matsukawa A, Litterio G, Cormio A, Miszczyk M, Kardoust Parizi M, Fazekas T, et al. An Updated Systematic Review and Network Meta-Analysis of First-Line Triplet vs. Doublet Therapies for Metastatic Hormone-Sensitive Prostate Cancer. Cancers. 2025;17:205.","DOI":"10.3390\/cancers17020205"},{"key":"1054_CR19","unstructured":"Dias S, Welton N, Sutton A, Ades A. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. Report by the Decision Support Unit. 2011. (last updated September 2016)"},{"key":"1054_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","volume":"14","author":"DC Hoaglin","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14:429\u201337.","journal-title":"Value Health"},{"key":"1054_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","volume":"14","author":"JP Jansen","year":"2011","unstructured":"Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14:417\u201328.","journal-title":"Value Health"},{"key":"1054_CR22","doi-asserted-by":"publisher","first-page":"782","DOI":"10.2471\/BLT.16.174326","volume":"94","author":"S Kanters","year":"2016","unstructured":"Kanters S, Ford N, Druyts E, Thorlund K, Mills EJ, Bansback N. Use of network meta-analysis in clinical guidelines. Bull World Health Organ. 2016;94:782\u20134.","journal-title":"Bull World Health Organ"},{"key":"1054_CR23","unstructured":"Chaimani A, Caldwell D, Li T, Higgins J, Salanti G Undertaking network meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). www.training.cochrane.org\/handbook.: Cochrane; 2021."},{"key":"1054_CR24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00406-016-0715-4","volume":"266","author":"S Leucht","year":"2016","unstructured":"Leucht S, Chaimani A, Cipriani AS, Davis JM, Furukawa TA, Salanti G. Network meta-analyses should be the highest level of evidence in treatment guidelines. Eur Arch Psychiatry Clin Neurosci. 2016;266:477\u201380.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1054_CR25","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1177\/0272989X13485157","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Welton NJ, Ades AE. Evidence synthesis for decision making 3: heterogeneity-subgroups, meta-regression, bias, and bias-adjustment. Med Decis Mak. 2013;33:618\u201340.","journal-title":"Med Decis Mak"},{"key":"1054_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1200\/JCO.2024.42.4_suppl.66","volume":"42","author":"AD Raval","year":"2024","unstructured":"Raval AD, Chen S, Littleton N, Constantinovici N, Goebell PJ. Underutilization of androgen deprivation therapy (ADT) intensification for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC): A systematic review of real-world database studies. J Clin Oncol. 2024;42:66.","journal-title":"J Clin Oncol"},{"key":"1054_CR27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2217\/fon-2023-0814","volume":"20","author":"PJ Goebell","year":"2024","unstructured":"Goebell PJ, Raina R, Chen S, Rege S, Shah R, Grossman JP, et al. Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia. Future Oncol. 2024;20:903\u201318.","journal-title":"Future Oncol"},{"key":"1054_CR28","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.5489\/cuaj.9110","volume":"19","author":"GT Gotto","year":"2025","unstructured":"Gotto GT, Yip SM, Shayegan B, O\u2019Sullivan DE, Wallis CJD, Basappa NS, et al. Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer. Can Urol Assoc J. 2025;19:E25\u2013E35.","journal-title":"Can Urol Assoc J"},{"key":"1054_CR29","doi-asserted-by":"publisher","first-page":"kab082","DOI":"10.1093\/jncics\/pkab082","volume":"5","author":"CJD Wallis","year":"2021","unstructured":"Wallis CJD, Malone S, Cagiannos I, Morgan SC, Hamilton RJ, Basappa NS, et al. Real-world use of androgen-deprivation therapy: Intensification among older Canadian men with de Novo metastatic prostate cancer. JNCI Cancer Spectr. 2021;5:kab082.","journal-title":"JNCI Cancer Spectr"},{"key":"1054_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41391-023-00775-y","volume":"27","author":"F Turco","year":"2024","unstructured":"Turco F, Gillessen S, Treglia G, Fizazi K, Smith MR, Tombal B, et al. Safety profile of darolutamide versus placebo: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2024;27:385\u201392.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1054_CR31","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/oncolo\/oyae019","volume":"29","author":"ND Shore","year":"2024","unstructured":"Shore ND, Gratzke C, Feyerabend S, Werbrouck P, Carles J, Vjaters E, et al. Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS. Oncologist. 2024;29:581\u20138.","journal-title":"Oncologist"},{"key":"1054_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.","journal-title":"Int J Surg"},{"key":"1054_CR33","doi-asserted-by":"crossref","unstructured":"Vickers AJ, Assel M, Dunn RL, MacLennan G, Becker BJ, Riley RD. Guidelines for meta-analyses and systematic reviews in urology. Eur Urol. 2025;88:421\u20136.","DOI":"10.1016\/j.eururo.2025.07.021"},{"key":"1054_CR34","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Mak. 2013;33:607\u201317.","journal-title":"Med Decis Mak"},{"key":"1054_CR35","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163\u201377.","journal-title":"Lancet"},{"key":"1054_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64:163\u201371.","journal-title":"J Clin Epidemiol"},{"key":"1054_CR37","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/0272989X12455847","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Mak. 2013;33:641\u201356.","journal-title":"Med Decis Mak"},{"key":"1054_CR38","unstructured":"Bujkiewicz S, Achana F, Papanikos T, Riley RD, Keith R. NICE DSU technical support document 20: Multivariate meta-analysis of summary data for combining treatment effects on correlated outcomes and evaluating surrogate endpoints. 2019. Available from http:\/\/www.nicedsu.org.uk."},{"key":"1054_CR39","doi-asserted-by":"publisher","first-page":"115513","DOI":"10.1016\/j.ejca.2025.115513","volume":"223","author":"N Shore","year":"2025","unstructured":"Shore N, Morgans AK, Boegemann M, Gallagher E, Paracha N, Serafini P, et al. Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis. Eur J Cancer. 2025;223:115513.","journal-title":"Eur J Cancer"},{"key":"1054_CR40","doi-asserted-by":"publisher","first-page":"e2034633","DOI":"10.1001\/jamanetworkopen.2020.34633","volume":"4","author":"UN Vaishampayan","year":"2021","unstructured":"Vaishampayan UN, Heilbrun LK, Monk P 3rd, Tejwani S, Sonpavde G, Hwang C, et al. Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2021;4:e2034633.","journal-title":"JAMA Netw Open"},{"key":"1054_CR41","doi-asserted-by":"publisher","first-page":"LBA5000","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5000","volume":"41","author":"A Bossi","year":"2023","unstructured":"Bossi A, Foulon S, Maldonado X, Sargos P, McDermott R, Flechon A, et al. Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design. J Clin Onc. 2023;41:LBA5000\u2013LBA.","journal-title":"J Clin Onc"},{"key":"1054_CR42","doi-asserted-by":"crossref","unstructured":"Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev. 2000:CD001526.","DOI":"10.1002\/14651858.CD001526"},{"key":"1054_CR43","unstructured":"Dias S, Sutton A, Welton N, Ades A. NICE DSU Technical Support Document 3: Heterogeneity: Subgroups, Meta-Regression, Bias and Bias-adjustment. Report by the Decision Support Unit. 2011 (last updated April 2012)."},{"key":"1054_CR44","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions: John Wiley & Sons; 2019 2019\/9\/23. 728.","DOI":"10.1002\/9781119536604"},{"key":"1054_CR45","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.euo.2022.06.003","volume":"5","author":"S Roy","year":"2022","unstructured":"Roy S, Sayyid R, Saad F, Sun Y, Lajkosz K, Ong M, et al. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis. Eur Urol Oncol. 2022;5:494\u2013502.","journal-title":"Eur Urol Oncol"},{"key":"1054_CR46","doi-asserted-by":"crossref","unstructured":"Dias SA, Welton AE, Nicky J, Jansen, Jeroen P, Alexander J, et al. Network Meta-Analysis for Decision-Making: John Wiley & Sons; 2018.","DOI":"10.1002\/9781118951651"},{"key":"1054_CR47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/jrsm.1219","volume":"8","author":"M Bennetts","year":"2017","unstructured":"Bennetts M, Whalen E, Ahadieh S, Cappelleri JC. An appraisal of meta-analysis guidelines: how do they relate to safety outcomes?. Res Synth Methods. 2017;8:64\u201378.","journal-title":"Res Synth Methods"},{"key":"1054_CR48","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: A Generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. National Institute for Health and Care Excellence (NICE); 2011."},{"key":"1054_CR49","doi-asserted-by":"crossref","unstructured":"Lunn D, Jackson C, Best N, Thomas A, Spiegelhalter DJ. The BUGS book: a practical introduction to Bayesian analysis. Boca Raton; London: CRC Press; 2013. xvii, 381 pages p.","DOI":"10.1201\/b13613"},{"key":"1054_CR50","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. https:\/\/www.R-project.org\/. Vienna, Austria: R Foundation for Statistical Computing; 2019."},{"key":"1054_CR51","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019;37:2974\u201386.","journal-title":"J Clin Oncol"},{"key":"1054_CR52","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373:737\u201346.","journal-title":"N Engl J Med"},{"key":"1054_CR53","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:149\u201358.","journal-title":"Lancet Oncol"},{"key":"1054_CR54","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018;36:1080\u20137.","journal-title":"J Clin Oncol"},{"key":"1054_CR55","doi-asserted-by":"publisher","first-page":"5081","DOI":"10.1200\/JCO.2022.40.16_suppl.5081","volume":"40","author":"A Tripathi","year":"2022","unstructured":"Tripathi A, Chen Y-H, Jarrard DF, Hahn NM, Garcia JA, Dreicer R, et al. Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. J Clin Oncol. 2022;40:5081.","journal-title":"J Clin Oncol"},{"key":"1054_CR56","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","volume":"76","author":"AP Hoyle","year":"2019","unstructured":"Hoyle AP, Ali A, James ND, Cook A, Parker CC, de Bono JS, et al. Abiraterone in \u201cHigh-\u201c and \u201cLow-risk\u201d Metastatic Hormone-sensitive Prostate Cancer. Eur Urol. 2019;76:719\u201328.","journal-title":"Eur Urol"},{"key":"1054_CR57","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/ijc.34018","volume":"151","author":"ND James","year":"2022","unstructured":"James ND, Clarke NW, Cook A, Ali A, Hoyle AP, Attard G, et al. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int J Cancer. 2022;151:422\u201334.","journal-title":"Int J Cancer"},{"key":"1054_CR58","doi-asserted-by":"crossref","unstructured":"Hoeh B, Garcia CC, Wenzel M, Tian Z, Tilki D, Steuber T, et al. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume. Eur Urol Focus. 2023;9:838\u201342.","DOI":"10.1016\/j.euf.2023.03.024"},{"key":"1054_CR59","doi-asserted-by":"crossref","unstructured":"Dias S, Ades A, Welton N, Jansen JP, Sutton A. Network Meta-Analysis for Decision-Making: Wiley; 2018.","DOI":"10.1002\/9781118951651"},{"key":"1054_CR60","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/rssa.12579","volume":"183","author":"DM Phillippo","year":"2020","unstructured":"Phillippo DM, Dias S, Ades AE, Belger M, Brnabic A, Schacht A, et al. Multilevel network meta-regression for population-adjusted treatment comparisons. J R Stat Soc Ser A Stat Soc. 2020;183:1189\u2013210.","journal-title":"J R Stat Soc Ser A Stat Soc"},{"key":"1054_CR61","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","volume":"24","author":"CL Vale","year":"2023","unstructured":"Vale CL, Fisher DJ, Godolphin PJ, Rydzewska LH, Boher JM, Burdett S, et al. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. Lancet Oncol. 2023;24:783\u201397.","journal-title":"Lancet Oncol"},{"key":"1054_CR62","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jrsm.1608","volume":"14","author":"O Harari","year":"2023","unstructured":"Harari O, Soltanifar M, Cappelleri JC, Verhoek A, Ouwens M, Daly C, et al. Network meta-interpolation: Effect modification adjustment in network meta-analysis using subgroup analyses. Res Synth Methods. 2023;14:211\u201333.","journal-title":"Res Synth Methods"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01054-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01054-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01054-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:03:32Z","timestamp":1786701812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01054-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1054"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-01054-8","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Neal Shore has received honoraria from Bayer, Janssen, Dendreon, Tolmar, Ferring, Astellas, Amgen, Pfizer, AstraZeneca, Merck, Sumitomo, Lantheus, Clarity, Telix, Daiichi-Sankyo,. Alicia Morgans has received honoraria from Astellas, AstraZeneca, AAA, Bayer, Exelixis, Lantheus, Novartis, Pfizer, Myovant, Myriad, Merck, Sanofi, Telix. Martin B\u00f6gemann has received honoraria from Astellas, AstraZeneca, AAA, Amgen, Bayer, Exelixis, Novartis, Pfizer, Lilly, MSD, BMS, Merck, Janssen, Gilead, EUSApham, Eisai. Noman Paracha and Elaine Gallaher are employees at Bayer HealthCare Pharmaceuticals Inc. Howard Thom is shareholder and David Aceituno and Philip Orishaba are employees of Clifton Insight which has received consulting fees from Bayer HealthCare Pharmaceuticals Inc., Novartis, MSD, Merck, Janssen, Pfizer, Daiichi-Sankyo, Eisai, Argenx, Amicus, Baxter, and Roche. Dr. Christopher Wallis is supported by the Hold\u2019em for Life Early Career Professor in Cancer Research, a University limited-term named professorship at the University of Toronto. Consulting Fees: Janssen Oncology, Nanostics Inc, Precision Point Specialty LLC, SESEN Bio; Honoraria\/Travel: AbbVie, Astellas, Astra Zeneca, Bayer, EMD Serono, Haymarket Media, Healing and Cancer Foundation, Intuitive Surgical, Knight Therapeutics, Merck, Science & Medicine Canada, Pfizer, TerSera Canada, Tolmar Pharmaceuticals Canada; Research Funding: Knight Therapeutics, Tolmar Pharmaceuticals, Bayer, Sunnybrook HSC AFP. Quoc-Dien Trinh reports consulting fees from Astellas, Bayer, Intuitive Surgical, Janssen, Novartis, Pfizer, and research funding from the American Cancer Society, Pfizer Global Medical Grants (Prostate Cancer Disparities #63354905), and a Health Disparity Research Award from the Department of Defense Congressionally Directed Medical Research Program (#PC220551). Keith Abrams is an ad hoc paid consultant to Bayer, as well as providing unrelated methodological and strategic advice to the pharmaceutical and life sciences industry. He has received unrelated research funding from Bayer, Association of the British Pharmaceutical Industry (ABPI), European Federation of Pharmaceutical Industries & Associations (EFPIA), Pfizer, Sanofi and Swiss Precision Diagnostics. He is a Partner and Director of Visible Analytics Limited. He is also a member of the NICE Diagnostics Advisory Committee, the NICE Decision and Technical Support Units, and is a National Institute for Health Research (NIHR) senior investigator emeritus. Stephen Stefani is an ad hoc paid consultant to Bayer, as well as providing unrelated methodological and strategic advice to the pharmaceutical and life sciences industry. He has received unrelated consultant fee from Bayer, Novartis, Astra Zeneca, Takeda, Beigene, Libbs, Adium and UNIMED. He is head of Health Technology Assessment for UNIMED Central RS and chair of the board of Americas Health Foundation.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Ethical approval was not required for this study because the study used previously published data and does not involve human participants or identifiable personal data.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}